A son of glembatumumab vedotin has just started its phase 1 study.
ApexOnco Front Page
Recent articles
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
Circle Pharma and Verismo feature in coveted sessions.
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
